Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji Kumar(Mayo Clinic), Philippe Moreau(Centre National de la Recherche Scientifique), Anjla Sood(AbbVie (United States)), Wan‐Jen Hong, Javier de la Rubia(Universitat de València), Cristina Gasparetto(Dana-Farber Cancer Institute), Jeremy A. Ross(AbbVie (United States)), Kevin J. Freise(AbbVie (United States)), Hans Salwender(Asklepios Klinik Altona), Michèle Cavo(Unknown), Muhammad Jalaluddin(AbbVie (United States)), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Paulo Maciag(AbbVie (United States)), Inho Kim(Seoul National University), Simon J. Harrison(Peter MacCallum Cancer Centre), Vânia Hungria(Faculdade de Ciências Médicas da Santa Casa de São Paulo), Xiaoqing Yang(Shandong University), Elizabeth A. Punnoose(University Hospital Cologne), James E. Ward(AbbVie (United States)), Kenshi Suzuki(Jikei University School of Medicine)
Cited by 401
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2016|1.1k